Essilor Cancels 1.5 Million Shares

Regulatory News :

At its meeting last November 25, the Board of Directors of Essilor International (Paris:EI) decided to cancel 1.5 million of the Company’s shares, representing 0.7% of the issued share capital. The decision was taken in accordance with the authorization granted in the tenth resolution approved by shareholders at the May 11, 2012 Combined Ordinary and Extraordinary Annual Meeting. The shares were cancelled effective December 3, 2013.

This transaction is in line with the Company’s policy of managing the dilutive impact of its stock option and employee share ownership plans.

Following the cancellation, there were 213,976,495 Essilor shares outstanding, of which 4,519,926, or 2.1% of the share capital, were held in treasury.

About Essilor
The world’s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®, Xperio^®, Optifog™ and Foster Grant^®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of nearly €5 billion in 2012 and employs around 50,700 people. It operates in more than 100 countries with 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world.
For more information, please visit www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.